ocugen_4C_LOGO (002).png
Ocugen, Inc. Appoints Huma Qamar, MD, MPH as Chief Medical Officer
March 18, 2024 06:30 ET | Ocugen
MALVERN, Pa., March 18, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene...
ocugen_4C_LOGO (002).png
Ocugen, Inc. Announces Dosing Completion of Subjects with Geographic Atrophy in Cohort 1 of Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410
March 13, 2024 08:00 ET | Ocugen
MALVERN, Pa., March 13, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene...
ocugen_4C_LOGO (002).png
Ocugen to Present at Investing in Cures Summit
March 06, 2024 07:30 ET | Ocugen
MALVERN, Pa., March 06, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and...
ocugen_4C_LOGO (002).png
Ocugen Clinical Showcase Webcast Now Available
February 28, 2024 08:00 ET | Ocugen
MALVERN, Pa., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and...
ocugen_4C_LOGO (002).png
Ocugen Chairman and CEO to present at Abu Dhabi Family Office Summit
February 26, 2024 08:30 ET | Ocugen
MALVERN, Pa., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene...
ocugen_4C_LOGO (002).png
Ocugen, Inc. Announces Dosing Completion of Subjects with Stargardt in Cohort 1 of Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410ST
February 22, 2024 16:05 ET | Ocugen
MALVERN, Pa., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene...
ocugen_4C_LOGO (002).png
Ocugen to Present at 2024 BIO CEO & Investor Conference
February 21, 2024 16:05 ET | Ocugen
MALVERN, Pa., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene...
ocugen_4C_LOGO (002).png
Ocugen to Host Clinical Showcase in New York City on Wednesday, February 21, 2024
February 14, 2024 07:30 ET | Ocugen
Highlighting updates on OCU400 Phase 3 clinical trial starting early 2024 Featuring thought leaders in gene therapy and OCU400 Phase 1/2 clinical trial patient MALVERN, Pa., Feb. 14, 2024 ...
ocugen_4C_LOGO (002).png
Ocugen to Present at Pharma Market Research Conference
January 31, 2024 08:00 ET | Ocugen
MALVERN, Pa., Jan. 31, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and...
ocugen_4C_LOGO (002).png
Ocugen, Inc. Announces Bob Smith Joins Business Advisory Board
January 16, 2024 07:30 ET | Ocugen
MALVERN, Pa., Jan. 16, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and...